We use cookies to improve your experience on this site. By viewing our pages, you give us consent to use cookies. Find out more.

Don’t invest unless you’re prepared to lose all the money you invest. NextFin promotes high - risk investments and you are unlikely to be protected if something goes wrong.
Take 2 minutes to learn more.

Equity Crowdfunding Pitches

Showing results
PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go: Extended investment: £295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go: Extended investment: Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go: TBC investment: £127,001
Morgan Goodwin is a UK-based company that pioneers the Combined Trading Platform (CTP) category, offering a comprehensive online platform for small businesses engaged in physical goods trading, along with specialized software development services, and a broad-spectrum business consultancy approach aimed at enhancing growth, efficiency, and technological advancement.
days to go: Stretch investment: £788,519
Doqit offers a solution for managing life admin tasks, helping you organize important information, set action dates, and receive timely reminders, ultimately streamlining tasks like insurance renewals and warranties to reduce unnecessary expenses and simplify your life. It provides secure storage and easy access for vital information, transitioning from chaos to simplicity.  Security is also a priority for Doqit. The platform ensures that your sensitive information is stored securely, giving you peace of mind knowing that you can access your important documents and data whenever you need them, all within a few clicks.
days to go: Extended investment: £87,500
UTU is a company dedicated to building the trust infrastructure for the evolving web 3.0. They aim to facilitate safer and more reliable interactions between users and platforms by utilizing a decentralized reputation and reviews protocol. This protocol involves a non-tradable reputation token (UTT) that users can stake to endorse others, leading to positive outcomes. UTU's focus initially lies in Web3 and DeFi apps, where they provide AI-powered tools to curate trust signals and help users engage confidently in various online activities. They offer a range of products, including the UTU Trust Token, Browser Extension, and Trust API/SDK, all aimed at enhancing trust and security in digital interactions.
days to go: Extended investment: £150,000
Care Line Live is an award-winning revolutionary monitoring and management platform for Home Care Agencies. CLL is a client-based system that enables home care agencies to run their businesses from any place. It reduces administration, automates processes, easily rosters client visits and improves efficiency and productivity by giving the client more Time to Care. It increases client and carer satisfaction, provides accessible and responsive support, increases compliance for CQC purposes, generates higher profits through improved efficiency and capacity. The future product road map includes integration with 3rd party home automation platforms that will allow home care agencies to offer further services to their clients, such as secure key-less entry.
days to go: Expired investment: £367,000
OPTIFarm is the world’s only real-time, remote, 24/7 optimisation service for livestock farms. The company argues that current livestock production facilities lack a systematic way of monitoring production, animal welfare or staff training needs on a continuous basis. It stresses that its model combines the knowledge of trained experts with raw data gathered from livestock consisting of metrics like feed consumption, feed availability, water, temperature, humidity, and air pressure. The company combines the aforementioned data with advanced software and data analytics offering livestock businesses 24/7 monitoring providing full status reports every 90 minutes. OPTIFarm asserts that this enables farms to optimise feed, water and climate to provide the best conditions for their livestock. OPTIFarm’s service is currently generating c. £25,000 per month in recurring revenues from poultry clients in 14 countries across the globe. The company stated it will use the investment received to prepare the business for rapid scale-up growth over the next five years.
days to go: Expired investment: Withheld
Nikalyte is a specialist in nanoparticles research and development (R&D) as well as commercialisation in various application areas such as cell binding, cell separation, drug delivery, catalysis, nano-photonics, and electrochemistry. The company is developing a nanoparticle generator, which will enable researchers to produce nanoparticles of almost any metal or alloy on almost any substrate via a user-friendly interface. Nikalyte is offering free nanoparticle samples to researchers investigating antiviral materials, such as Copper and Silver, towards developing a vaccine for Covid-19. The company also offers a consultancy service that provides advice on nanoparticle applications and ultra-high vacuum systems. The company aims to use the investment to scale its business.

Pitch Rated

37%

Insufficient Data

rating powered by

CROWD RATING™

days to go: Expired investment: Withheld
Iceni Labs is an innovative enterprise that develops and deploys cutting-edge technologies to build a safer and secure future. The company takes early-stage technology from the lab to the market by partnering with leading academics, researchers, and commercial experts. It has collaborated with the UK National Health Service’s (NHS) Royal Papworth Hospital to accelerate the development of a non-contact device, SafeScan, that monitors the breathing rate of an individual remotely. Iceni Labs also conducted a one-year clinical study of the device at Royal Papworth Hospital on a sample size of 400 patients. It has been awarded Innovate UK funding to build a prototype for monitoring care home residents. The company's goal is to become globally recognised as a catalyst for successful innovation.
days to go: Expired investment: Withheld
  • Internet Business Awards Category Award Winner 2015
  • Hertfordshire Business Awards Finalist 2014

As seen in:

  • The Guardian
  • Financial Times
  • Yahoo! Finance
  • The Times
  • The Daily Telegraph